Weiss Multi-Strategy Advisers’s Aclaris Therapeutics ACRS Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,368	Closed	-$345K	–	526
2023 Q3	$345K	Sell	50,368 -70,574	-58%	-$603K	0.01%	497
2023 Q2	$1.25M	Buy	120,942 +61,980	+105%	+$561K	0.03%	523
2023 Q1	$477K	Buy	+58,962	New	+$748K	0.01%	558
2022 Q3	–	Sell	-15,000	Closed	-$209K	–	641
2022 Q2	$209K	Buy	+15,000	New	+$210K	0.01%	610

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ACRS Position: Q4 2023 in Review

Weiss Multi-Strategy Advisers sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 50,368 shares — an estimated $345K sold.

Weiss Multi-Strategy Advisers first reported a position in ACRS in Q2 2022 and held it in 4 quarters. The position peaked at $1.25M in Q2 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Weiss Multi-Strategy Advisers reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 50,368 Aclaris Therapeutics shares in Q4 2023, an estimated $345K.
Weiss Multi-Strategy Advisers first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 4 quarters.
Weiss Multi-Strategy Advisers's Aclaris Therapeutics position peaked at $1.25M in Q2 2023.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.